India Pharma Outlook Team | Wednesday, 03 September 2025
Future presentations at the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight (EIS), the 25th European Society of Retina Specialists (EURETINA) Congress.
The Retina Society Annual Congress have been announced by Oculis Holding AG (Oculis), a global biopharmaceutical company that focuses on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs.In addition to enhanced data analysis from Stage 1 of the phase 3 DIAMOND program on subgroups by lens status and prior treatmtent status, Oculis will disclose clinical trials results from its novel late-stage pipeline.
The findings demonstrate how OCS-01 may help a range of DME patient profiles, such as phakic and pseudophakic individuals, as well as patients who have never had treatment before and those who have.
Also Read: Alcon launches UNITY surgical platforms in India
The 25th EURETINA Congress's late-breaking session will feature data from the phase 2 ACUITY trial examining Privosegtor (OCS-05), a possible neuroprotective treatment for acute optic neuritis. The trial's previously released headline results demonstrated clinically significant improvements in visual function and anatomical neuroprotection benefits in patients receiving Privosegtor, indicating its use in a number of neurological, neuro-ophthalmological, and retinal disorders.
At the EURETINA inauguration ceremony on September 4, 2025, the annual Ramin Tadayoni Award winner will also be revealed. The prize, which was created by EURETINA in collaboration with Oculis, honors the memory of Professor Tadayoni, a distinguished retina specialist and former chief scientific officer of Oculis. By honoring a distinguished postgraduate researcher who has the potential to significantly expand our knowledge of and ability to treat retinal diseases, this renowned award encourages creative research.
